{"title":"Xanomeline-Trospium Chloride (Cobenfy)：治疗精神分裂症的新时代——比较有效性和经济挑战","authors":"Jawairya Muhammad Hussain, Wajiha Arif, Sharjeel Humayun, Nida Shoaib, Saim Mahmood Khan","doi":"10.1002/med4.70013","DOIUrl":null,"url":null,"abstract":"<p>Xanomeline-trospium chloride (cobenfy) is a muscarinic agonist used to treat hallucinations and psychotic illnesses such as Alzheimer's and Schizophrenia. It has been constructed for patients who are unable to tolerate dopamine-targeting therapies and a comparison is drawn against other similar drugs with variables like cost, mechanism of action, efficacy and contraindications taken into account. Specifically effective for schizophrenia, it is safer with fewer side effects and efficient with stronger success rates, offering pharmacists and physicians an alternative to mainstream antipsychotic drugs.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"116-121"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70013","citationCount":"0","resultStr":"{\"title\":\"Xanomeline-Trospium Chloride (Cobenfy): A New Era in Managing Schizophrenia—Comparative Effectiveness and Economic Challenges\",\"authors\":\"Jawairya Muhammad Hussain, Wajiha Arif, Sharjeel Humayun, Nida Shoaib, Saim Mahmood Khan\",\"doi\":\"10.1002/med4.70013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Xanomeline-trospium chloride (cobenfy) is a muscarinic agonist used to treat hallucinations and psychotic illnesses such as Alzheimer's and Schizophrenia. It has been constructed for patients who are unable to tolerate dopamine-targeting therapies and a comparison is drawn against other similar drugs with variables like cost, mechanism of action, efficacy and contraindications taken into account. Specifically effective for schizophrenia, it is safer with fewer side effects and efficient with stronger success rates, offering pharmacists and physicians an alternative to mainstream antipsychotic drugs.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":100913,\"journal\":{\"name\":\"Medicine Advances\",\"volume\":\"3 2\",\"pages\":\"116-121\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70013\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine Advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/med4.70013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine Advances","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med4.70013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Xanomeline-Trospium Chloride (Cobenfy): A New Era in Managing Schizophrenia—Comparative Effectiveness and Economic Challenges
Xanomeline-trospium chloride (cobenfy) is a muscarinic agonist used to treat hallucinations and psychotic illnesses such as Alzheimer's and Schizophrenia. It has been constructed for patients who are unable to tolerate dopamine-targeting therapies and a comparison is drawn against other similar drugs with variables like cost, mechanism of action, efficacy and contraindications taken into account. Specifically effective for schizophrenia, it is safer with fewer side effects and efficient with stronger success rates, offering pharmacists and physicians an alternative to mainstream antipsychotic drugs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
